LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "first recurrence" as a keyword



Do the benefits of IDH mutations in high-grade glioma persist beyond the first recurrence? A multi-institutional retrospective analysis

Sign Up to like & get
recommendations! Published in 2025 at "Journal of Neuro-Oncology"

DOI: 10.1007/s11060-025-05049-2

Abstract: Recurrence is inevitable in both IDH wild-type glioblastoma and IDH-mutant WHO grade 3 or 4 astrocytoma. While IDH-mutant astrocytomas are associated with longer survival and delayed first progression, less is known about disease course beyond… read more here.

Keywords: idh wild; time; wild type; first recurrence ... See more keywords

MBCL-26. FACTORS ASSOCIATED WITH LONGER SURVIVAL AFTER FIRST RECURRENCE IN MEDULLOBLASTOMA BY MOLECULAR SUBGROUP AFTER RISK-BASED INITIAL THERAPY

Sign Up to like & get
recommendations! Published in 2020 at "Neuro-Oncology"

DOI: 10.1093/neuonc/noaa222.502

Abstract: Abstract OBJECTIVE To evaluate differences in time to recurrence among molecular subgroups of medulloblastoma treated on a single protocol and to identify factors associated with survival after first recurrence. METHODS Time to recurrence following SJMB03… read more here.

Keywords: first recurrence; risk; recurrence; value ... See more keywords

NIMG-35. IMPACT OF RESECTION AT TIME OF FIRST RECURRENCE IN WHO GRADE 2 IDH-MUTANT GLIOMAS

Sign Up to like & get
recommendations! Published in 2024 at "Neuro-Oncology"

DOI: 10.1093/neuonc/noae165.0800

Abstract: Maximal safe resection standard of care treatment of IDH-mutant gliomas and is associated with improved overall survival (OS). However, the impact of extent of resection (EOR) at first recurrence is not well established and there… read more here.

Keywords: resection; flair; first recurrence; eor ... See more keywords

Bevacizumab at first recurrence after standard radio-chemotherapy is associated with improved overall survival in glioblastoma patients with large tumor burden.

Sign Up to like & get
recommendations! Published in 2019 at "Neuro-oncology practice"

DOI: 10.1093/nop/npy021

Abstract: Background Since its approval for use in recurrent glioblastoma (GBM), the survival benefit of bevacizumab (Bev) remains to be demonstrated. To address this issue, we retrospectively examined survival from first recurrence in patients treated with… read more here.

Keywords: first recurrence; patients large; bev; tumor ... See more keywords

Abstract CT103: Final results for OptimalTTF-1: Optimizing Tumor Treating Fields with targeted skull remodeling surgery for first recurrence glioblastoma: Phase 1 trial

Sign Up to like & get
recommendations! Published in 2020 at "Cancer Research"

DOI: 10.1158/1538-7445.am2020-ct103

Abstract: Background: We present a clinical open label, phase-1 trial (OptimalTTF-1, NCT02893137), which aims to test a novel treatment for first recurrence glioblastoma (rGBM). The aim of the treatment is to optimize the electric field generated… read more here.

Keywords: first recurrence; surgery; trial; recurrence glioblastoma ... See more keywords
Photo by nci from unsplash

Phase II study of pembrolizumab plus SurVaxM for glioblastoma at first recurrence.

Sign Up to like & get
recommendations! Published in 2020 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2020.38.15_suppl.tps2581

Abstract: TPS2581Background: Glioblastoma is the most common primary malignant brain tumor with median survival of approximately 15-16 months. Following first recurrence, progression free survival at six mon... read more here.

Keywords: first recurrence; glioblastoma; pembrolizumab plus; study pembrolizumab ... See more keywords

Characterizing platinum resistance in recurrent endometrial cancer: A retrospective cohort study.

Sign Up to like & get
recommendations! Published in 2025 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2025.43.16_suppl.e17620

Abstract: e17620 Background: Endometrial cancer is the most diagnosed gynecologic malignancy in Western countries, with a lifetime risk of approximately 2.5% in the United States. Twenty-nine percent of patients present with advanced-stage disease. The risk of… read more here.

Keywords: treatment; platinum based; non platinum; first recurrence ... See more keywords

AB022. Management of first recurrence or progression of craniopharyngioma after resection alone: a systematic review and individual-participant data meta-analysis.

Sign Up to like & get
recommendations! Published in 2024 at "Chinese clinical oncology"

DOI: 10.21037/cco-24-ab022

Abstract: BACKGROUND The initial management of craniopharyngioma is generally either gross total resection (GTR) or subtotal resection (STR) with adjuvant radiotherapy (RT). However, the optimal management strategy for recurrent/progressive craniopharyngioma remains unclear. METHODS PubMed and Embase… read more here.

Keywords: craniopharyngioma; resection; progression; recurrence progression ... See more keywords